Clinical Trial: A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07789964) titled 'A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants' on Aug. 20.

Brief Summary: This is a randomised, double-blind, two-arm, parallel group, single-dose study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of ixekizumab (SB35 and Taltz) in healthy participants.

Study Start Date: Sept. 02

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: Ixekizumab

80 mg, single-dose

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Samsung Bioepis Co., Ltd.

Disclaimer: Curated by HT Syndication....